TY  - JOUR
AB  - Describes Myriad Genetics and its struggle to secure exclusive testing services for the BRCA gene. After Myriad obtained licensing rights and dissolved its U.S. competition, it turned its focus to Europe, specifically the United Kingdom. The U.K. National Health Service had made genetic testing available to the public and Myriad had to decide which course of action would be most effective in stopping British BRCA genetic testing and expanding Myriad's own service to this new market.
VL  - 
IS  - 
SN  - 2474-6568
DO  - 10.1108/case.kellogg.2016.000225
UR  - https://doi.org/10.1108/case.kellogg.2016.000225
AU  - Diermeier Daniel
AU  - Parthasarathy Shobita
PY  - 2017
Y1  - 2017/01/01
TI  - Myriad (A): Breast Cancer Testing in Britain
T2  - Kellogg School of Management Cases
PB  - Kellogg School of Management
SP  - 1
EP  - 14
Y2  - 2024/05/07
ER  -